NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights

--Jean-Frédéric Viret, Ph.D., has been appointed as Chief Financial Officer effective November 3, 2023-- --Continued to progress myeloid checkpoint solid tumor programs: NGM707, NGM831 and NGM438--...

Related Keywords

United States ,Boston ,Massachusetts ,Davidj Woodhouse , ,Merck Sharp Dohme ,Merck Co Inc ,Merck Sharp Dohme Corp ,Anesiva Inc ,Exchange Commission ,Shasqi Inc ,Coherus Biosciences Inc ,Blade Therapeutics Inc ,Dexus Inc ,Caredx Inc ,Biopharmaceuticals Inc ,Xdx Inc ,Tularik Inc ,Chief Financial Officer ,Liver Meeting ,Chief Executive Officer ,Third Quarter ,Coherus Biosciences ,Blade Therapeutics ,Merck Sharp ,Dohme Corp ,Alphabetical Order ,Immunoglobin Like Transcript ,Leukocyte Associated Immunoglobulin Like Receptor ,Private Securities Litigation Reform Act ,Quarterly Report ,United States Securities ,Markets ,